Skip to content

Pharmacists’ perspectives on psilocybin in Canada

Elizabeth Sugiarto, Rebecca Leung, Jamie Yuen

JAPhA Practice Innovations November 8, 2023 DOI: 10.1016/j.japhpi.2023.100003 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Survey Peer reviewed
Population Licensed pharmacists in Canada
Topics Psilocybin
Keywords Hallucinogen
Citations 1
Key findings Most pharmacists lack formal education about psilocybin and are not comfortable making recommendations or monitoring its use, yet they are open to a role in psilocybin therapy.

Abstract

AbstractBackground Psilocybin is the main psychoactive component of a naturally occurring psychedelic organism commonly referred to as "magic mushrooms." Existing literature demonstrates beneficial neurologic effects in treatment-resistant depression, cancer-associated depression and anxiety, and substance use. The evidence base for psilocybin use is on the rise with the U.S. Food and Drug Administration owing to a resurgence in clinical research. As such, pharmacists need to be adequately equipped to navigate questions from consumers and care providers. There is currently no literature describing pharmacists' perspectives on psilocybin. Evaluating pharmacists' knowledge, experiences, and opinions about psilocybin may yield beneficial and applicable data to develop educational programs and clinical tools and guide psilocybin policy making.

Objective: The objective of this study was to evaluate the interest and opinions of pharmacists on psilocybin as an emerging therapeutic option.

Methods: Licensed pharmacists in Canada were invited to participate in an anonymous, online, 44-item survey aimed at evaluating pharmacists' experiences, knowledge, and attitudes toward psilocybin. Recruitment for the study was done through multiple Canadian pharmacy association newsletters and via LinkedIn.

Results: Results showed that 73% of pharmacists lacked formal education about psilocybin. Forty percent of pharmacists had conversations about psilocybin less than once a month whereas 60% of pharmacists have never received questions about psilocybin. Furthermore, pharmacists are not comfortable with their knowledge with making recommendations (75%), monitoring (57%), or recommending doses of psilocybin (64%) to patients.

Conclusion: Pharmacists are open to embracing a role in psilocybin therapy and dispensing. Creation of clinical practice guidelines and increased accessibility to education materials are necessary to supplement pharmacists' knowledge on psilocybin and improve their confidence when advising patients.

Comparable studies

Other cross-sectional and survey studies on psilocybin, most cited first.

Study Year Design Participants
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... 2016 Cross-sectional survey n = 1,993
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin 2016 Questionnaire development and validation
Psychedelics and Mental Health: A Population Study Adult population in the United States 2013 Cross-sectional survey n = 130,152
Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... 2019 Cross-sectional survey n = 343
Patterns of simultaneous polysubstance use in drug using university students Drug-using university students 2006 Cross-sectional survey n = 149

Citations in the library

Explore topics